NO20004896L - Pyridazinonhydrokloridforbindelse og fremgangsmÕte for fremstilling derav - Google Patents

Pyridazinonhydrokloridforbindelse og fremgangsmÕte for fremstilling derav

Info

Publication number
NO20004896L
NO20004896L NO20004896A NO20004896A NO20004896L NO 20004896 L NO20004896 L NO 20004896L NO 20004896 A NO20004896 A NO 20004896A NO 20004896 A NO20004896 A NO 20004896A NO 20004896 L NO20004896 L NO 20004896L
Authority
NO
Norway
Prior art keywords
preparation
pyridazinone
hydrochloride compound
pyridazinone hydrochloride
carbonylmethoxy
Prior art date
Application number
NO20004896A
Other languages
English (en)
Other versions
NO20004896D0 (no
Inventor
Takashi Horiuchi
Sachiko Matsumoto
Hiroo Matsumoto
Minako Kamikawaji
Original Assignee
Nissan Chemical Ind Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nissan Chemical Ind Ltd filed Critical Nissan Chemical Ind Ltd
Publication of NO20004896D0 publication Critical patent/NO20004896D0/no
Publication of NO20004896L publication Critical patent/NO20004896L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/22—Nitrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/12—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Det er beskrevet et 3/2-hydroklorid av 4-klor-5-[3-(4-benzylpiperazin-1- yl)karbonylmetoksy-4-metoksybenzylamino]-3(2H)-pyridazinon, og også en fremgangsmåte for fremstilling av 3/2-hydrokloridet av 4-klor-5-[3-(4- benzylpiperazin-1-yl)karbonylmetoksy-4-metoksybenzylamino]-3(2H)- pyridazinon som omfatter krystallisering i alkoholtypeoppløsningsmiddel eller et alkoholtype-estertypeblandet oppløsningsmiddel l nærvær av hydrogen- klorid og vann.
NO20004896A 1998-03-31 2000-09-29 Pyridazinonhydrokloridforbindelse og fremgangsmÕte for fremstilling derav NO20004896L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP8592098 1998-03-31
PCT/JP1999/001629 WO1999050248A1 (en) 1998-03-31 1999-03-30 Pyridazinone hydrochloride compound and method for producing the same

Publications (2)

Publication Number Publication Date
NO20004896D0 NO20004896D0 (no) 2000-09-29
NO20004896L true NO20004896L (no) 2000-10-12

Family

ID=13872231

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20004896A NO20004896L (no) 1998-03-31 2000-09-29 Pyridazinonhydrokloridforbindelse og fremgangsmÕte for fremstilling derav

Country Status (14)

Country Link
US (1) US6310065B1 (no)
EP (1) EP1066265A1 (no)
JP (1) JP2002509919A (no)
KR (1) KR20010042078A (no)
CN (1) CN1293661A (no)
AU (1) AU742553B2 (no)
CA (1) CA2326506A1 (no)
IL (1) IL138521A0 (no)
NO (1) NO20004896L (no)
NZ (1) NZ506959A (no)
SK (1) SK14742000A3 (no)
TW (1) TW499425B (no)
WO (1) WO1999050248A1 (no)
ZA (1) ZA200004927B (no)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
EA030606B1 (ru) 2006-05-04 2018-08-31 Бёрингер Ингельхайм Интернациональ Гмбх Способы приготовления лекарственного средства, содержащего полиморфы
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
MX2011002558A (es) 2008-09-10 2011-04-26 Boehringer Ingelheim Int Terapia de combinacion para el tratamiento de diabetes y estados relacionados.
US8978895B2 (en) * 2008-10-01 2015-03-17 Rickey E. Wark Self-cleaning coal separator grids with multiple cleaning combs
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
CN102256976A (zh) 2008-12-23 2011-11-23 贝林格尔.英格海姆国际有限公司 有机化合物的盐形式
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
EA034869B1 (ru) 2009-11-27 2020-03-31 Бёрингер Ингельхайм Интернациональ Гмбх Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин
KR101819609B1 (ko) 2010-05-05 2018-01-17 베링거 인겔하임 인터내셔날 게엠베하 체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법
KR20230051307A (ko) 2010-06-24 2023-04-17 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
MX366629B (es) 2011-07-15 2019-07-17 Boehringer Ingelheim Int Quinazolinas sustituidas, su preparación y su uso en composiciones farmacéuticas.
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP2849755A1 (en) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
JP6218811B2 (ja) 2012-05-14 2017-10-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｉｒｓ及び／又は敗血症の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
WO2015128453A1 (en) 2014-02-28 2015-09-03 Boehringer Ingelheim International Gmbh Medical use of a dpp-4 inhibitor
US10155000B2 (en) 2016-06-10 2018-12-18 Boehringer Ingelheim International Gmbh Medical use of pharmaceutical combination or composition

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL110040A (en) * 1993-06-29 2000-07-16 Nissan Chemical Ind Ltd Pyridazinone derivatives their preparation and pharmaceutical compositions comprising them
JP3080131B2 (ja) * 1993-06-29 2000-08-21 日産化学工業株式会社 ピリダジノン誘導体

Also Published As

Publication number Publication date
WO1999050248A1 (en) 1999-10-07
IL138521A0 (en) 2001-10-31
NZ506959A (en) 2002-02-01
EP1066265A1 (en) 2001-01-10
AU2960699A (en) 1999-10-18
ZA200004927B (en) 2001-12-24
KR20010042078A (ko) 2001-05-25
TW499425B (en) 2002-08-21
NO20004896D0 (no) 2000-09-29
AU742553B2 (en) 2002-01-03
CA2326506A1 (en) 1999-10-07
CN1293661A (zh) 2001-05-02
SK14742000A3 (sk) 2001-03-12
US6310065B1 (en) 2001-10-30
JP2002509919A (ja) 2002-04-02

Similar Documents

Publication Publication Date Title
NO20004896L (no) Pyridazinonhydrokloridforbindelse og fremgangsmÕte for fremstilling derav
DK177585D0 (da) Pyridazinoner
TW347387B (en) Piperidine derivatives
AU563448B2 (en) Substituted 4,5-dihydro-6-(substituted)-phenyl-3(2h)- pyridazinones and 6-(substituted)phenyl-3(2h)-pyridazinones
DK417185A (da) 4,5-dihydro-3(2h)-pyridazinoner, fremgangsmaade til fremstilling derafog deres anvendelse
NO964813L (no) Fremgangsmåte for stabilisering av duocarmycinderivater
AU8722991A (en) Arylpyridazinones
DK0567271T3 (da) Steroidderivater til behandling af prostatahypertrofi, fremgangsmåde til fremstilling heraf og anvendelser heraf
ATE34741T1 (de) 6-(acylaminoaryl)-3(2h)-pyridazinonderivate, ihre herstellung und verwendung.
DK129282A (da) Fremgangsmaade til fremstilling af indolylethylderivater
CA2226894A1 (en) 2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives
CA2129013A1 (en) Pyridinecarboximidamide compounds and the use thereof
CA2385200A1 (en) 4-hydroxybiphenyl hydrazide derivatives
MX9806211A (es) Composiciones herbicidas estables que contienen quelados metalicos de compuestos herbicidas de dionas.
NO950974L (no) Nye N,N,N',N'-tetrasubstituert-1,2-etandiaminderivatforbindelser
ES8506002A1 (es) Procedimiento para la obtencion de 2-(1-indolinil-metil)-imidazolinas
JPS539321A (en) Agri-horticultural fungicide
ATE27453T1 (de) 6-aryl-4,5-dihydro-3(2h)-pyridazinone,ihre herstellung und verwendung.
BR9815967A (pt) Processo para a preparação de um derivado de amino-5-cloro de 3(2h)-piridazinona-4-substituìdo
DK0788472T3 (da) Fremgangsmåde til fremstilling af 5,6-dihydroxy-2-amino-1,2,3,4-tetrahydronaphthalenderivater
NO952913L (no) Forbedret fremgangsmåte og sammensetning for delignifisering av et lignocellulosemateriale
DK0869957T3 (da) 3(2H)-Pyridazinonderivater og farmaceutiske sammensætninger indeholdende disse forbindelser
GR3006342T3 (no)
JPS54135785A (en) Pyridazinone derivative and its preparation
Yamamoto Application of Sound Insulation Technique for Piano Lesson Room in Apartment House

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application